Neuren Pharmaceuticals Limited (ASX:NEU)

Neuren Pharmaceuticals Revenue

Neuren Pharmaceuticals had revenue of 33.16M AUD in the half year ending June 30, 2026, with 26.32% growth. This brings the company's total for the last twelve months to 69.53M, down -68.23% year-over-year. In the year 2025, Neuren Pharmaceuticals had annual revenue of 64.65M, down -70.18%. That makes Neuren Pharmaceuticals the 28,167th largest company in the world by revenue and 487th in Australia.

• Revenue (ttm): 69.53M
• Revenue Growth: -68.23%
• P/S Ratio: 34.10
• Revenue / Employee: 8.69M
• Employees: 8
• Market Cap: 2.37B

Revenue Chart

Chart

Chart

Revenue by Segment

Chart

• Commercial Products 64.63M 100.0%
• Corporate 15.00K 0.0%

Fiscal year ended Dec 31, 2025 See the full Neuren Pharmaceuticals breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	64.65M	-152.18M	-70.18%
Dec 31, 2024	216.83M	-15.11M	-6.51%
Dec 31, 2023	231.94M	216.53M	1,404.46%
Dec 31, 2022	15.42M	12.22M	382.23%
Dec 31, 2021	3.20M	2.48M	345.89%

Data Source: S&P Global Market Intelligence Last updated: Aug 25, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Oct 26, 2026

Data Sources Report a data error